In:
Dementia and Geriatric Cognitive Disorders, S. Karger AG, Vol. 23, No. 3 ( 2007), p. 150-160
Abstract:
〈 i 〉 Background/Aims: 〈 /i 〉 Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. 〈 i 〉 Methods: 〈 /i 〉 The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer’s disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. 〈 i 〉 Results: 〈 /i 〉 The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0–4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4–10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5–16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. 〈 i 〉 Conclusion: 〈 /i 〉 Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.
Type of Medium:
Online Resource
ISSN:
1420-8008
,
1421-9824
Language:
English
Publisher:
S. Karger AG
Publication Date:
2007
detail.hit.zdb_id:
1482186-2
Permalink
